Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Topigen completes enrollment of Phase II asthma trial
The current clinical study builds on prior efficacy and safety data in a three-day study of TPI ASM8 in an allergen challenge model. TPI ASM8 is a novel,
The current clinical study builds on prior efficacy and safety data in a three-day study of TPI ASM8 in an allergen challenge model. TPI ASM8 is a novel,
Interim results from the study indicate that significantly higher anti-nicotine antibody levels can be generated three months earlier and in a much higher percentage of subjects than observed
The Phase III Glass-Art trial is designed to determine the survival benefit derived from, and safety of, adding Neuradiab to the current standard of care therapy, consisting of
To evaluate the role of norepinephrine (NE) in fibromyalgia and the safety and efficacy of Droxidopa in this indication, Chelsea intends to conduct an exploratory Phase II trial
The first agreement with the University of Louisville’s James Graham Brown Cancer Center grants Advanced Cancer Therapeutics (ACT) exclusive worldwide development and commercialization rights to monovalent vaccines derived
Michael DeLaGarza, president and CEO of AMSS and PayMed, will assume the position of president of MedCom USA, once the acquisition is finalized. He has worked in the
Under the agreement Novartis will provide Dynavax a supply of trivalent influenza vaccine, an essential component of Dynavax’s Universal Influenza Vaccine, for both clinical trial use and vaccine
Under the terms of the agreement, Spiration and Olympus will work exclusively with each other to gain regulatory approval for the IBV valve system in Japan. Olympus will
ImmunoCellular Therapeutics (IMUC) is advancing its monoclonal antibodies toward clinical trials, and humanizing the antibodies will provide for a safer therapeutic with less immunogenicity potential. IMUC, through its
The study showed that treatment of hormone resistant human prostate cancer in tumor bearing mouse models with intravenous pegylated-rHuPH20 enzyme (PEGPH20) in combination with the chemotherapeutic drugs, docetaxel